Qualitative Patient Experiences of Hemolytic Disease of the Fetus and Newborn (HDFN): Psychosocial Impacts Reported During an Ongoing Patient Council

Lisa Shea¹, Maartje Mangelaars², Carrie Yavuz³, Colleen Moore⁴, Emily Clifford⁵

¹Johnson & Johnson, Horsham, PA, USA; ²Johnson & Johnson, the Netherlands, Breda, Netherlands; ³HDFN Global Patient Council Advisory Board member, Scotland, UK; ⁴The NemetzGroup LLC, Boston, MA, USA; ⁵Center for Information and Study on Clinical Trial Participation (CISCRP), Boston, MA, USA

as having prior HDFN experience

Background



Hemolytic disease of the fetus and newborn (HDFN) is a rare disease where maternal antibodies, or alloantibodies, produced in a pregnant person's immune system cross the placenta and attack fetal red blood cells, causing fetal hemolysis leading to anemia¹



There is no approved treatment for HDFN; although intrauterine transfusions (IUTs) can improve fetal survival, they are invasive and carry a 5%–10% overall perinatal mortality as well as risks such as bradycardia, bleeding, and fetal loss²; intravenous immunoglobulin (IVIG) treatment may delay timing of the first IUT³



A 2025 systematic review of the literature concluded that there is a need for further representative observational studies to aid a greater understanding of the burden and experience of HDFN⁴

Objectives



The objective of this analysis was to identify patient-directed themes to better understand the experience and unmet needs of HDFN-affected pregnancies

Number of IUTs

Methods

HDFN Global Patient Council Advisory Boards



 Members were recruited via patient advocacy groups and through healthcare provider referrals

Patient council members were adults (aged ≥18 years) who self-reported

- Seven touchpoints (TPs) were held from September 2021 to January 2024 using semi-structured interview guides
- There were a total of 14 sessions (meetings/interviews) across each TP (TP1, n=6; TP2 and TP4, n=2 each; all others, n=1 each); each session yielded a separate transcript
- Patient quotes were de-identified in transcripts

Transcript Analysis



 Transcripts were reviewed manually to identify key themes around patient experiences related to their condition, which were annotated in Microsoft Word

 Annotated transcripts were uploaded into MAXQDA for analysis and reference, extracting specific patient quotes around their journey

Future decisions to

conceive are difficult;

emotional trauma

occurs with subsequent

pregnancies

Key Takeaways



Patients feel the need to self-advocate, which contributes to the stress, anxiety, and trauma impacting quality of life. Social support and personalized, responsive medical care is highly valued




Practical considerations of HDFN care place a substantial burden on patients' lives and put pressure on family and personal relationships



The short- and long-term implications of alloimmunization/HDFN are unclear, and patients experience a lack of comprehensive, and coordinated care. Additional education on HDFN recognition and management is needed for HCPs beyond the maternal-fetal medicine specialist

Results




Prior Treatment


IUT, intrauterine transfusion; *IVIG*, intravenous immunoglobulin.

Pillar 1: Need for self-advocacy to ensure appropriate care

HCP, healthcare professional; HDFN, hemolytic disease of the fetus and newborn; IUT, intrauterine transfusion; IVIG, intravenous immunoglobulin.



Pillar 2: Lifestyle and emotional impacts; trauma and guilt with childbearing



"I think trying to go back into that situation and putting yourself back into that situation as a mother, knowing what has previously

happened, and having those experiences, is very, very difficult. And very traumatic actually. I hadn't anticipated maybe how traumatic